An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide Each Given With Radiation Therapy for Newly-diagnosed Patients With Glioblastoma (GBM a Malignant Brain Cancer)

Brief description of study

The purpose of this study is to evaluate patients with glioblastoma that is MGMT-unmethylated
(the MGMT gene is not altered by a chemical change). Patients will receive Nivolumab every
two weeks in addition to radiation therapy, and then every four weeks. They will be compared
to patients receiving standard therapy with temozolomide in addition to radiation therapy.